Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 16/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.48 |
| ▸ | NOS3 | P29474 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | NOS2 | P35228 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL4322246 | 0.90 | SLC6A2 (0.53) | SLC6A2SLC6A4CYP2D6KCNH2SLC6A3 | |
| SCHEMBL5286650 | 0.90 | SLC6A2 (0.55) | SLC6A2SLC6A4CYP2D6KCNH2SLC6A3 | |
| SCHEMBL4316564 | 0.90 | SLC6A2 (0.55) | SLC6A2SLC6A4CYP2D6KCNH2SLC6A3 | |
| SCHEMBL4324834 | 0.88 | SLC6A2 (0.54) | SLC6A2SLC6A4CYP2D6KCNH2SLC6A3 | |
| SCHEMBL4324930 | 0.87 | SLC6A2 (0.61) | SLC6A2SLC6A4CYP2D6KCNH2SLC6A3 | |
| SCHEMBL4321553 | 0.87 | SLC6A2 (0.52) | SLC6A2SLC6A4CYP2D6KCNH2SLC6A3 | |
| SCHEMBL4327407 | 0.87 | SLC6A4 (0.54) | SLC6A2SLC6A4CYP2D6KCNH2SLC6A3 | |
| SCHEMBL4317568 | 0.87 | SLC6A2 (0.61) | SLC6A2SLC6A4CYP2D6KCNH2SLC6A3 | |
| Cadaverine Tartrate SCHEMBL4326826 | 0.81 | SLC6A2 (0.54) | SLC6A2SLC6A4CYP2D6KCNH2SLC6A3 | |
| SCHEMBL4327753 | 0.81 | SLC6A2 (0.57) | SLC6A2SLC6A4CYP2D6KCNH2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615648-B2 | Aminomethyl-azacycle derivatives as inhibitors of monoamine uptake | ELI LILLY AND COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615648-B2 | Aminomethyl-azacycle derivatives as inhibitors of monoamine uptake | ELI LILLY AND COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615648-B2 | Aminomethyl-azacycle derivatives as inhibitors of monoamine uptake | ELI LILLY AND COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080004330-A1 | Aminomethyl-Azacycle Derivatives as Inhibitors of Monoamine Uptake | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
| US-20080004330-A1 | Aminomethyl-Azacycle Derivatives as Inhibitors of Monoamine Uptake | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
| US-20080004330-A1 | Aminomethyl-Azacycle Derivatives as Inhibitors of Monoamine Uptake | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004330-A1 | Aminomethyl-Azacycle Derivatives as Inhibitors of Monoamine Uptake | SLC6A2, TPH1, SLC6A3 | SLC6A2 1/4885SLC6A4 8/4885CYP2D6 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.